Highlights

  • Island Pharmaceuticals secured AUD 9m through a one-tranche placement of new shares.
  • Funding supports Galidesivir’s FDA Animal Rule development and NDA submission process.
  • Capital will also be applied to Ebola and Sudan virus US stockpile programs.

Island Pharmaceuticals Ltd (ASX:ILA) has announced firm commitments to raise AUD 9m through a private placement involving the issue of 25,714,285 fully paid ordinary shares at AUD 0.35 per share. The placement attracted participation from a combination of local and international institutional, sophisticated, and professional investors, with a US-based family office acting as a cornerstone investor.

The issue price represents a 10% discount to the last traded price and a 17.94% discount to the 15-day volume-weighted average price (VWAP) of AUD 0.4265. Shares will be issued under the company’s available placement capacity in accordance with ASX Listing Rule 7.1A and will rank equally with existing ordinary shares.

Funding Position and Use of Proceeds
The placement proceeds add to Island’s existing cash balance of AUD 6.87m as at 31 December 2025. Combined funding is intended to fully support the company’s two-stage FDA Animal Rule development pathway for its antiviral candidate Galidesivir, including preparation and submission of a New Drug Application (NDA) to the US Food and Drug Administration.

In parallel, capital will be allocated toward the manufacture of additional Galidesivir supply to meet clinical development requirements and potential commercial readiness. Funds will also be directed to regulatory and pre-clinical work associated with additional US Government Strategic National Stockpile opportunities targeting Ebola and Sudan virus.

Regulatory Framework and Strategic Relevance
The funding follows recent alignment with the FDA regarding Galidesivir’s proposed development pathway under the Animal Rule, which allows approval based on animal efficacy data where human trials are not feasible, subject to defined regulatory standards.

Approval under this pathway may enable eligibility for US Government procurement, including potential inclusion in the Strategic National Stockpile. In addition, successful approval could qualify the program for a Priority Review Voucher (PRV), with recent disclosed transactions valuing such vouchers at approximately USD 200m.

Placement Execution and Timeline
The placement will be completed in a single tranche. Settlement is scheduled for 13 February 2026, with allotment and trading of the new shares expected on 16 February 2026. ORA Capital acted as lead manager and bookrunner and will receive a 6% fee on funds raised.

Market Snapshot
Island Pharmaceuticals shares were trading at AUD 0.44, up 12.82%.